South Africa HIV Therapeutics Market Analysis Report [2022-30]

South Africa HIV Therapeutics Market Analysis

$ 3999

The South Africa HIV therapeutics market is expected to reach $xx Mn by 2030, up from $89.44 Mn in 2022, with a CAGR of xx% from 2022 to 2030. Local Players such as Cipla Medpro, Adcock Ingram, and Aspen Pharmacare dominate the HIV therapeutics market in South Africa. The government policies, funding, and initiatives by international organizations to manage highly prevalent HIV infections in the country propel market growth. The HIV therapeutics market in South Africa is divided into four segments: type, product, geography, end user, and distribution channel.

ID: IN10ZAPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: South Africa AUTHOR: Dr. Vishwa Modhia

Buy Now

South Africa HIV Therapeutics Market Analysis Summary

South Africa is a country on the African continent's southernmost tip. It also includes the Prince Edward Islands, a small sub-Atlantic archipelago. The HIV therapeutics market in South Africa is expected to reach $xx Mn by 2030, up from $89.44 Mn in 2022, at a CAGR of xx % from 2022 to 2030.

South Africa has the fourth-highest HIV prevalence rate in the world, at 19.10 %. Given the country's large population, this percentage equates to 7.8 Mn HIV-positive people, more than any other country and roughly one-fifth of all HIV cases worldwide. According to the most recent WHO data, HIV/AIDS deaths in South Africa reached 71,996 in 2020, accounting for 15.84 % of total deaths.

South Africa ranks ninth in the world with an age-adjusted death rate of 121.35 per 100,000 population. The AIDS Foundation South Africa is a healthcare organization that works to improve the lives of people living with HIV. In 2020, South Africa spent 8.6 % of its GDP on healthcare.

south africa HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

The country has the largest ART program in the world, with 68 percent of HIV patients receiving ART by 2021 and 93 % of those patients achieving viral load suppression. HIV/AIDS was also to blame for South Africa's average life expectancy falling to less than 43 years in 2008; it has since risen to 65 years as of 2022. HIV/AIDS remains a serious public health threat, despite the fact that awareness campaigns and the increased availability of anti-retroviral drugs are reducing the number of new cases, allowing infected people to live longer, healthier lives, and reducing mother-child transmissions. HIV transmission from mother to child during birth has decreased from 3.5 % in 2010 to less than 1% in 2021. These factors may entice new entrants into the HIV therapeutics market in South Africa.

Market Restraint

South Africa continues to face skills shortages in several critical industries, including health care and technology. These factors may deter new entrants into the HIV therapeutics market in South Africa.

Competitive Landscape

Key Players

Aspen Pharmacare (ZAF)
Adcock Ingram (ZAF)
Cipla Medpro (ZAF)
Mylan (ZAF)
Sonke Pharmaceuticals (ZAF)
ViiV Healthcare
Bristol Myers Squibb
Merck & Co.
Gilead Sciences

Recent Notable Update

March 2022: The injection, developed by ViiV Healthcare and approved by the US Food and Drug Administration, provides two months of HIV protection and contains the active ingredient cabotegravir. The World Health Organization (WHO) hosted the ground-breaking announcement, which is hoped will boost HIV prevention globally. As an alternative to daily medication, the first injection to provide long-term HIV protection is being rolled out in South Africa and Brazil.

Healthcare Regulations and Reimbursement Policies

The South African government has established the South African Health Products Regulatory Authority (SAHPRA) to oversee the registration, licensing, and regulation of all health products in the country, including HIV therapeutics. SAHPRA is in charge of assessing the safety, efficacy, and quality of all medicines and health products before they can be used in South Africa. Furthermore, the South African government has undertaken a number of initiatives to increase access to HIV therapeutics. The National Strategic Plan for HIV, Tuberculosis, and Sexually Transmitted Infections 2017-2022 is one such initiative.

The National Department of Health manages the reimbursement of HIV therapeutics in the public health system, allocating funding to provinces for the provision of ART. Provincial health departments are in charge of managing the distribution of ART to clinics and hospitals, where it is given to people living with HIV for free. Medical schemes, which are private health insurance plans, typically manage reimbursement for HIV therapeutics in the private health sector. The Council for Medical Schemes regulates medical schemes, overseeing their operations and ensuring compliance with industry regulations.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.